Literature DB >> 18460953

Clinical assessment of heart-type fatty acid binding protein in early diagnosis of acute coronary syndrome.

Hector Alonso Valle1, Luis García-Castrillo Riesgo, Miguel Sántalo Bel, Francisco Epelde Gonzalo, Miguel Sánchez Sanchez, Luis Iglesias Oliva.   

Abstract

BACKGROUND: Early identification of acute coronary syndrome (ACS) in the emergency room is still a difficult task. The objective of this study is to estimate the reliability of heart-type fatty acid binding protein (H-FABP) in identifying ACS in the early stage of chest pain onset.
METHODS: In a prospective multicentre study in emergency room patients with suspected ACS lasting less than 3 h, heart heart-type fatty acid binding protein (H-FABP) was compared with conventional biomarkers. Protein levels >7 ng/ml were considered positive results.
RESULTS: A total of 419 patients were analyzed. Acute myocardial infarction was diagnosed in 148 patients (35%). H-FABP sensitivity was 60% (89 out of 148 patients), significantly higher than troponin T [19% (28 out of 148 patients); P<0,05]. Specificity of troponin T, however, [99% (270 out of 271 patients)] was better than H-FABP [88% (237 out of 271 patients)], though this was not statistically significant.
CONCLUSION: H-FABP can be a useful early diagnostic biochemical marker, particularly within the first 6 h of symptoms, in patients attending the emergency department.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18460953     DOI: 10.1097/MEJ.0b013e3282efd47a

Source DB:  PubMed          Journal:  Eur J Emerg Med        ISSN: 0969-9546            Impact factor:   2.799


  8 in total

1.  Heart-type fatty acid binding protein is an independent predictor of death and ventricular dysfunction after coronary artery bypass graft surgery.

Authors:  Jochen D Muehlschlegel; Tjörvi E Perry; Kuang-Yu Liu; Amanda A Fox; Charles D Collard; Stanton K Shernan; Simon C Body
Journal:  Anesth Analg       Date:  2010-05-10       Impact factor: 5.108

2.  Comparative study of high sensitivity troponin T and heart-type fatty acid-binding protein in STEMI patients.

Authors:  Shaheena Banu; Syed Tanveer; C N Manjunath
Journal:  Saudi J Biol Sci       Date:  2014-06-10       Impact factor: 4.219

3.  The role of heart-type fatty acid-binding protein in the diagnosis of acute coronary syndrome.

Authors:  Jonathan Rosman; Gita Kavala; Kotoro Obunai; Steven R Bergmann
Journal:  Int J Angiol       Date:  2009

4.  Comparison of the new high sensitive cardiac troponin T with myoglobin, h-FABP and cTnT for early identification of myocardial necrosis in the acute coronary syndrome.

Authors:  Kerstin Kurz; Evangelos Giannitsis; Maike Becker; Georg Hess; Dietmar Zdunek; Hugo A Katus
Journal:  Clin Res Cardiol       Date:  2010-09-18       Impact factor: 5.460

5.  Value of heart-type fatty acid-binding protein (H-FABP) for emergency department patients with suspected acute coronary syndrome.

Authors:  Karakus Yilmaz Banu; Ozüçelik Doğaç Niyazi; Cevik Erdem; Doğan Hatice Dpekçi Afşin; Uzun Ozlem; Celik Yasemin; Ipekci Afsin
Journal:  Afr Health Sci       Date:  2014-09       Impact factor: 0.927

6.  Heart-type fatty acid-binding protein: an overlooked cardiac biomarker.

Authors:  Harsh Goel; Joshua Melot; Matthew D Krinock; Ashish Kumar; Sunil K Nadar; Gregory Y H Lip
Journal:  Ann Med       Date:  2020-08-04       Impact factor: 4.709

7.  Development of a Point-of-Care Test Based on Selenium Nanoparticles for Heart-Type Fatty Acid-Binding Proteins in Human Plasma and Blood.

Authors:  Lanju Wang; Mengli Wu; Jingjing Ma; Ziwei Ma; Jiahui Liang; Ningya Tao; Yangguang Ren; Shujun Shao; Xin Qi; Zhizeng Wang
Journal:  Int J Nanomedicine       Date:  2022-03-22

8.  Multi-Marker Approach with the Use of Biochip Cardiac Array Technology for Early Diagnosis in Patients with Acute Coronary Syndromes.

Authors:  Marcin Sawicki; Grazyna Sypniewska; Magdalena Krintus; Marek Kozinski; Joanna Ostrowska-Nowak; Marta Pilaczyńska-Cemel; Dominika Budzbon; Kubica Jacek
Journal:  EJIFCC       Date:  2008-12-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.